TY - JOUR
T1 - Levosimendan Efficacy and Safety 20 Years of SIMDAX in Clinical Use
AU - ---
AU - Papp, Zoltán
AU - Agostoni, Piergiuseppe
AU - Alvarez, Julian
AU - Bettex, Dominique
AU - Bouchez, Stefan
AU - Brito, Dulce
AU - Černý, Vladimir
AU - Comin-Colet, Josep
AU - Crespo-Leiro, Marisa G.
AU - Delgado, Juan F.
AU - Édes, István
AU - Eremenko, Alexander A.
AU - Farmakis, Dimitrios
AU - Fedele, Francesco
AU - Fonseca, Cândida
AU - Fruhwald, Sonja
AU - Girardis, Massimo
AU - Guarracino, Fabio
AU - Harjola, Veli Pekka
AU - Heringlake, Matthias
AU - Herpain, Antoine
AU - Heunks, Leo M.A.
AU - Husebye, Tryggve
AU - Ivancan, Višnja
AU - Karason, Kristjan
AU - Kaul, Sundeep
AU - Kivikko, Matti
AU - Kubica, Janek
AU - Masip, Josep
AU - Matskeplishvili, Simon
AU - Mebazaa, Alexandre
AU - Nieminen, Markku S.
AU - Oliva, Fabrizio
AU - Papp, Julius G.
AU - Parissis, John
AU - Parkhomenko, Alexander
AU - Põder, Pentti
AU - Pölzl, Gerhard
AU - Reinecke, Alexander
AU - Ricksten, Sven Erik
AU - Riha, Hynek
AU - Rudiger, Alain
AU - Sarapohja, Toni
AU - Schwinger, Robert H.G.
AU - Toller, Wolfgang
AU - Tritapepe, Luigi
AU - Tschöpe, Carsten
AU - Wikström, Gerhard
AU - Lewinski, Dirk Von
AU - Vrtovec, Bojan
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
AB - Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
KW - acute heart failure
KW - advanced heart failure
KW - hemodynamics
KW - inodilator
KW - inotrope
KW - neurohormone
KW - regulatory clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85088209844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088209844&partnerID=8YFLogxK
U2 - 10.1097/FJC.0000000000000859
DO - 10.1097/FJC.0000000000000859
M3 - Review article
C2 - 32639273
AN - SCOPUS:85088209844
VL - 76
SP - 4
EP - 22
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
SN - 0160-2446
IS - 1
ER -